Negotiations on Purchase and Selling Prices for Prescription Drugs and SG&A Expense Reduction
First written in FY2016. 8 of 10 entries say "Restated". Latest entry: FY2021.
1 other company's latest entry also says "Advanced".
- FY2021AdvancedAnnual report
「Of the ¥2.1 trillion in prescription pharmaceutical sales in the fiscal year ended March 2021, the percentage of transaction prices determined, on a value basis, was 99.9%, and transaction prices tend to be almost fully determined by the end of the fiscal year.」
The company disclosed a 99.9% transaction-price determination rate for the fiscal year ended March 2021 in connection with price negotiations and transaction-price management in accordance with the Distribution Improvement Guidelines. - FY2020-Q3RestatedAnnual report
「We are also negotiating prices aligned with the characteristics and value of individual products, based on the Guidelines for Distribution Improvement of Prescription Pharmaceuticals to Be Observed by Distribution Stakeholders formulated by the Ministry of Health, Labour and Welfare.」
The company continues its policy of negotiating prices aligned with product characteristics and value, in accordance with the Distribution Improvement Guidelines. - FY2020-Q2RestatedAnnual report
「We are also negotiating prices aligned with the characteristics and value of individual products, based on the Guidelines for Distribution Improvement of Prescription Pharmaceuticals to Be Observed by Distribution Stakeholders formulated by the Ministry of Health, Labour and Welfare.」
The company continues its policy of negotiating prices aligned with product characteristics and value, in accordance with the Distribution Improvement Guidelines. - FY2019-Q3RestatedAnnual report
「We are also working to negotiate prices aligned with the characteristics and value of individual products, based on the Guidelines for Distribution Improvement of Prescription Pharmaceuticals to Be Observed by Distribution Stakeholders formulated by the Ministry of Health, Labour and Welfare.」
The company continues its policy of securing appropriate profits through price negotiations aligned with product characteristics and value, in accordance with the Distribution Improvement Guidelines. - FY2019-Q2RestatedAnnual report
「We are also working to negotiate prices aligned with the characteristics and value of individual products, based on the Guidelines for Distribution Improvement of Prescription Pharmaceuticals to Be Observed by Distribution Stakeholders formulated by the Ministry of Health, Labour and Welfare.」
The company continues its policy of improving distribution and securing profits through price negotiations aligned with product characteristics and value. - FY2019-Q1RestatedAnnual report
「We are also working to improve distribution, including through price negotiations aligned with the characteristics and value of individual products, and striving to secure appropriate profits.」
The company continues its policy of improving distribution and securing appropriate profits through price negotiations aligned with product characteristics and value. - FY2018RestatedAnnual report
「We are working to improve distribution, including through price negotiations aligned with the characteristics and value of individual products.」
The company continues its policy of improving distribution and securing profits through price negotiations aligned with product characteristics and value. - FY2017-Q2RestatedAnnual report
「Meanwhile, we negotiated purchase prices for individual pharmaceutical products and, based on those negotiations, negotiated selling prices with customers, working to secure profits.」
The company continues to secure profits through negotiations over purchase prices for individual products and corresponding negotiations over selling prices with customers. - FY2017-Q1RestatedAnnual report
「We also negotiated purchase prices for individual pharmaceutical products and, based on those negotiations, negotiated selling prices with customers, working to secure profits.」
The company continues efforts to secure profits through negotiations over purchase prices for individual products and corresponding negotiations over selling prices with customers. - FY2016First statedAnnual report
「While steadily negotiating selling prices with customers, we reduced SG&A expenses through measures such as improving logistics efficiency and worked to secure profits.」
The company is seeking to secure profits in its pharmaceutical wholesaling business by combining price negotiations with reductions in SG&A expenses through more efficient logistics.